Usha Ganesh
Impact in
- Infectious Diseases top 2%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
Papers in
-
- Innovation and Socioeconomic Development 2
-
- SARS-CoV-2 and COVID-19 Research 3
Usha Ganesh
13 papers receiving 1.8k citations
Usha Ganesh's Hit Papers
Peers
Comparison fields: 5 of 114
- Infectious Diseases 963
- Applied Microbiology and Biotechnology 50
- Neurology 344
- Internal Medicine 56
- Obstetrics and Gynecology 86
Countries citing papers authored by Usha Ganesh
This map shows the geographic impact of Usha Ganesh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Usha Ganesh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Usha Ganesh more than expected).
Fields of papers citing papers by Usha Ganesh
This network shows the impact of papers produced by Usha Ganesh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Usha Ganesh. The network helps show where Usha Ganesh may publish in the future.
Co-authors
The 2 scholars most cited alongside Usha Ganesh, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 403 |
| 2 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 381 |
| 3 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 4 | 1997 | 240 | |
| 5 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 230 |
| 6 | Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 211 |
| 7 | 2023 | 83 | |
| 8 | 2023 | 24 | |
| 9 | 2024 | 23 | |
| 10 | 2025 | 5 | |
| 11 | 2025 | 2 | |
| 12 | 2017 | 1 | |
| 13 | Corridors for shared prosperity : transfer journeys of Indian inclusive business models | 2017 | 1 |
| 14 | 2019 | 1 |
About Usha Ganesh
Usha Ganesh is a scholar working on Business and International Management, Infectious Diseases, Management of Technology and Innovation, Finance and Organizational Behavior and Human Resource Management, having authored 14 papers that have together received 1.9k indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (3 papers), Innovation and Socioeconomic Development (2 papers), Community Development and Social Impact (1 paper), Innovation and Knowledge Management (1 paper), Corporate Finance and Governance (1 paper), Business Strategy and Innovation (1 paper), Family Business Performance and Succession (1 paper) and Indian Economic and Social Development (1 paper). The work is most often cited by research in Infectious Diseases (963 citations), Applied Microbiology and Biotechnology (50 citations), Neurology (344 citations), Internal Medicine (56 citations) and Obstetrics and Gynecology (86 citations). Usha Ganesh has collaborated with scholars based in Australia, United Kingdom and Vietnam. Frequent co-authors include Mona Makhija and Satyajit Majumdar. Their work appears in journals such as The Lancet, The Lancet Infectious Diseases, EClinicalMedicine, Organization Science and The Lancet Child & Adolescent Health.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.